Unity Biotechnology (NASDAQ:UBX) Cut to Neutral at Wedbush :

Wedbush lowered shares of Unity Biotechnology (NASDAQ:UBX – Free Report) from an outperform rating to a neutral rating in a research note published on Monday, The Fly reports. Several other analysts have also recently issued reports on the company. Mizuho dropped their target price on Unity Biotechnology from $12.00 to $6.00 and set a buy […]

Related Keywords

, Arete Wealth Advisors , Unity Biotechnology Inc , Nasdaq , Capital Investment Advisors , Citigroup , Schonfeld Strategic Advisors , Unity Biotechnology , Free Report , Moderate Buy , Wealth Advisors , Street Group , Strategic Advisors , Two Sigma Investments , Unity Biotechnology Daily ,